Sai Life Sciences announces plans to recruit 500+ scientists in 2021

• Immediately initiates first phase of recruitment for 100 scientists in API process development and scale-up
• To initiate recruitment for 400 positions across Discovery Chemistry, Biology & DMPK in a phased manner over the year

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), today announced its plans to recruit over 500 scientists during the year 2021. As the first phase of this drive, the company has initiated recruitment for scientific talent in API process and analytical research & development, particle science and engineering , niche platform technologies as well as life cycle management.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences said, “Over the past 18-24 months we have been significantly augmenting our R&D facilities and rapidly growing our customer outreach. We expect these efforts to bear fruit in the coming months and are therefore looking to expand our team. This addition to our high-quality talent pool will help us better serve our customers by accelerating their projects involving complex chemistry and next generation technologies.”

As part of the current recruitment drive, the company is looking to on-board top-notch global scientific talent with M.Sc./ Ph.D / Post Doctorates in synthetic organic / analytical chemistry from reputed academic institutions, and experience in global pharma R&D of up to 20 years, across various levels. The company also has positions open for Technology Transfer focused Process Engineers and Program Managers. The full list of open positions can be viewed here.

Marking
the completion of 20 years since its inception in 2019, the company announced Sai
Nxt, an organisation-wide initiative aimed at transforming itself into a
new generation CRO/CDMO. Guided by the insights and
feedback from its customers, it committed to investing over US$150M between
2019 and 2023 to significantly expand and upgrade its R&D and manufacturing
facilities, deepen scientific & technological capabilities, strengthen
automation and data systems, and above all raise the bar for safety, quality
and customer focus.

As
part of Sai Nxt, the company has added 172 KL API & Intermediate
manufacturing capacity, opened a discovery biology Lab in Cambridge,
Massachusetts, USA, a centre of excellence in process R&D in Manchester, UK
and an 83,000 sq. ft. integrated research & technology facility in
Hyderabad with technology platforms including flow chemistry, biocatalysis and
crystallization. It became the first India-headquartered company to join
Pharmaceutical Supply Chain Initiative (PSCI). The company is now in the
process of adding high potent capability in R&D and manufacturing, a new
clean room block and 200KL additional manufacturing capacity.